| Company Name | Bayer Taiwan Co., Ltd. |
|---|---|
| Protocol Number | 21283 |
| Title of Study | XATOC – Xarelto + Acetylsalicylic Acid: Treatment patterns and Outcomes across the disease Continuum in patients with CAD and/or PAD |
| Primary Objective | To describe general health status, as reported by CAD or symptomatic PAD patients treated with rivaroxaban 2.5 mg [BID] plus ASA 75-100 mg [OD] in routine clinical practice, to describe treatment patterns in CAD or symptomatic PAD patients treated with rivaroxaban 2.5 mg [BID] plus ASA 75-100 mg [OD] in routine clinical practice |
| Number of Sites | 11 |
| Period of Study | From：2020/11/01 to：2020/12/31 |
| Number of Patients | 200人 |
| IRB Approval Date | KSVGH: 2020/09/01 KMUH: 2020/09/11 LKCGMH/KSCGMH: 2020/09/01 ChiMei: 2020/09/25 CMUH: 2020/09/14 MMH: 2020/09/24 |
| Publication Plan / Date | Unknown |
